JP2021515542A5 - - Google Patents
Info
- Publication number
- JP2021515542A5 JP2021515542A5 JP2020542297A JP2020542297A JP2021515542A5 JP 2021515542 A5 JP2021515542 A5 JP 2021515542A5 JP 2020542297 A JP2020542297 A JP 2020542297A JP 2020542297 A JP2020542297 A JP 2020542297A JP 2021515542 A5 JP2021515542 A5 JP 2021515542A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- antigen
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1803745.7A GB201803745D0 (en) | 2018-03-08 | 2018-03-08 | PD1 binding agents |
| GB1803745.7 | 2018-03-08 | ||
| GB1807176.1 | 2018-05-01 | ||
| GBGB1807176.1A GB201807176D0 (en) | 2018-03-08 | 2018-05-01 | PD1 Binding agents |
| GB1811302.7 | 2018-07-10 | ||
| GBGB1811302.7A GB201811302D0 (en) | 2018-03-08 | 2018-07-10 | PD1 binding agents |
| GB1816372.5 | 2018-10-08 | ||
| GBGB1816372.5A GB201816372D0 (en) | 2018-03-08 | 2018-10-08 | PD1 binding agents |
| GB1817652.9 | 2018-10-29 | ||
| GBGB1817652.9A GB201817652D0 (en) | 2018-03-08 | 2018-10-29 | PD1 binding agents |
| PCT/EP2019/055901 WO2019170885A1 (en) | 2018-03-08 | 2019-03-08 | Pd1 binding agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021515542A JP2021515542A (ja) | 2021-06-24 |
| JP2021515542A5 true JP2021515542A5 (enExample) | 2022-03-15 |
| JP7419238B2 JP7419238B2 (ja) | 2024-01-22 |
Family
ID=61972774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542297A Active JP7419238B2 (ja) | 2018-03-08 | 2019-03-08 | Ｐｄ１結合剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10858434B2 (enExample) |
| EP (1) | EP3762418A1 (enExample) |
| JP (1) | JP7419238B2 (enExample) |
| KR (1) | KR20200128544A (enExample) |
| CN (1) | CN111819201A (enExample) |
| AU (1) | AU2019229663A1 (enExample) |
| CA (1) | CA3092169A1 (enExample) |
| GB (5) | GB201803745D0 (enExample) |
| IL (1) | IL277131A (enExample) |
| SG (1) | SG11202008240RA (enExample) |
| WO (1) | WO2019170885A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201803745D0 (en) | 2018-03-08 | 2018-04-25 | Ultrahuman Eight Ltd | PD1 binding agents |
| GB201803746D0 (en) | 2018-03-08 | 2018-04-25 | Ultrahuman Eight Ltd | PD1 binding agents |
| GB201914747D0 (en) * | 2019-10-11 | 2019-11-27 | Ultrahuman Eight Ltd | PD1 and vegfr2 dual-binding agents |
| CA3181776A1 (en) | 2020-05-26 | 2021-12-02 | Boehringer Ingelheim International Gmbh | Anti-pd-1 antibodies |
| CN116194471A (zh) | 2020-06-23 | 2023-05-30 | 卡德门企业有限公司 | 抗pd-1抗体和融合蛋白 |
| EP4353746A4 (en) * | 2021-06-11 | 2024-12-04 | Guangdong Fapon Biopharma Inc. | Anti-pd-1 humanized antibody or antigen-binding fragment thereof and application thereof |
| US11981727B2 (en) * | 2021-08-31 | 2024-05-14 | Novelmed Therapeutics, Inc | Monospecific and bispecific antibodies and antigen binding fragments thereof |
| CN116253796A (zh) * | 2022-09-21 | 2023-06-13 | 三优生物医药(上海)有限公司 | 靶向冠状病毒的中和抗体、其抗原结合片段及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101218257A (zh) * | 2005-03-25 | 2008-07-09 | 托勒克斯股份有限公司 | Gitr结合分子及其用途 |
| EP3530736A3 (en) * | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| PT2170959E (pt) * | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| ES2742379T3 (es) | 2012-05-31 | 2020-02-14 | Hoffmann La Roche | Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 y antagonistas de VEGF |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| MA43028B1 (fr) * | 2015-10-02 | 2021-09-30 | Hoffmann La Roche | Anticorps bispécifiques pour pd1 et tim3 |
| GB201803745D0 (en) | 2018-03-08 | 2018-04-25 | Ultrahuman Eight Ltd | PD1 binding agents |
| GB201803746D0 (en) | 2018-03-08 | 2018-04-25 | Ultrahuman Eight Ltd | PD1 binding agents |
-
2018
- 2018-03-08 GB GBGB1803745.7A patent/GB201803745D0/en not_active Ceased
- 2018-05-01 GB GBGB1807176.1A patent/GB201807176D0/en not_active Ceased
- 2018-07-10 GB GBGB1811302.7A patent/GB201811302D0/en not_active Ceased
- 2018-10-08 GB GBGB1816372.5A patent/GB201816372D0/en not_active Ceased
- 2018-10-29 GB GBGB1817652.9A patent/GB201817652D0/en not_active Ceased
-
2019
- 2019-03-08 WO PCT/EP2019/055901 patent/WO2019170885A1/en not_active Ceased
- 2019-03-08 SG SG11202008240RA patent/SG11202008240RA/en unknown
- 2019-03-08 AU AU2019229663A patent/AU2019229663A1/en not_active Abandoned
- 2019-03-08 EP EP19710388.0A patent/EP3762418A1/en not_active Withdrawn
- 2019-03-08 CA CA3092169A patent/CA3092169A1/en active Pending
- 2019-03-08 CN CN201980017469.7A patent/CN111819201A/zh active Pending
- 2019-03-08 KR KR1020207027823A patent/KR20200128544A/ko not_active Withdrawn
- 2019-03-08 JP JP2020542297A patent/JP7419238B2/ja active Active
-
2020
- 2020-06-25 US US16/911,826 patent/US10858434B2/en not_active Expired - Fee Related
- 2020-09-03 IL IL277131A patent/IL277131A/en unknown
- 2020-11-02 US US17/086,762 patent/US11851460B2/en active Active
-
2023
- 2023-11-14 US US18/508,501 patent/US20240124590A1/en not_active Abandoned